B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy

Journal of Neuroscience Research

Volumn 88, Issue 10, 2010, Pages 2207-2216

  Palazzolo, Isabella ^a,b   Nedelsky, Natalia B ^c,d   Askew, Caitlin E ^a   Harmison, George G ^a   Kasantsev, Aleksey G ^e   Taylor, J Paul ^c   Fischbeck, Kenneth H ^a   Pennuto, Maria ^f  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Androgen receptor; B2; Inclusions; Polyglutamine disease; SBMA

Indexed keywords

5 [4 (4 CHLOROBENZOYL) 1 PIPERAZINYL] 8 NITROQUINOLINE; ANDROGEN RECEPTOR; B 2; MUTANT PROTEIN; NITROQUINOLINE DERIVATIVE; POLYGLUTAMINE; UNCLASSIFIED DRUG; 5-(4-(4-CHLOROBENZOYL)-1-PIPERAZINYL)-8-NITROQUINOLINE; LIGAND; NEUROPROTECTIVE AGENT; PEPTIDE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DROSOPHILA; DRUG EFFECT; DRUG EFFICACY; HUMAN; KENNEDY DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; BULBO-SPINAL ATROPHY, X-LINKED; CELL LINE; CELL NUCLEUS INCLUSION BODY; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG EFFECTS; GENETICS; INTRACELLULAR SPACE; METABOLISM; MUTATION; PROTEIN MULTIMERIZATION; RAT; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BULBO-SPINAL ATROPHY, X-LINKED; CELL LINE; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; HUMANS; INTRACELLULAR SPACE; INTRANUCLEAR INCLUSION BODIES; LIGANDS; MUTATION; NEUROPROTECTIVE AGENTS; NITROQUINOLINES; PEPTIDES; PIPERAZINES; PROTEIN MULTIMERIZATION; RATS; RECEPTORS, ANDROGEN;

EID: 77953648932     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22389     Document Type: Article

References (48)

1. Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Yoshida M, Hashizume Y, Sobue G. 2005. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128:659-670.
2. Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, Sobue G. 2007. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol Appl Neurobiol 33:135-151. (Pubitemid 46385721)
3. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805-810.
4. Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K, Yamada S, Oki Y, Adachi H, Minamiyama M, Waza M, Atsuta N, Watanabe H, Fujimoto Y, Nakashima T, Tanaka F, Doyu M, Sobue G. 2009. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65:140-150.
5. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG. 2006. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A 103:4246-4251.
6. Brooks BP, Paulson HL, Merry DE, Salazar-Grueso EF, Brinkmann AO, Wilson EM, Fischbeck KH. 1997. Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis 3:313-323.
7. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868. (Pubitemid 29165088)
8. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A, Orr HT, Beaudet AL, Zoghbi HY. 1999. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24:879-892. (Pubitemid 30017667)
9. Faus H, Haendler B. 2008. Androgen receptor acetylation sites differentially regulate gene control. J Cell Biochem 104:511-524.
10. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG. 2000. p300 And p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853-20860.
11. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Janne OA, Muratoglu S, Avantaggiati ML, Pestell RG. 2003. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563-8575.
12. Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, Powell MJ, Yang T, Gu W, Avantaggiati ML, Pattabiraman N, Pestell TG, Wang F, Quong AA, Wang C, Pestell RG. 2006. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 26:8122-8135.
13. Garcia-Mata R, Bebok Z, Sorscher EJ, Sztul ES. 1999. Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 146:1239-1254.
14. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. 2006. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311:1471-1474.
15. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. 2007. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 67:4514-4523.
16. Holtz-Heppelmann CJ, Algeciras A, Badley AD, Paya CV. 1998. Transcriptional regulation of the human FasL promoter-enhancer region. J Biol Chem 273:4416-4423.
17. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G. 2002. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843-854.
18. Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G. 2003. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768-773.
19. Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, Doyu M, Sobue G. 2006. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 200:8-18.
20. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79.
21. Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G. 1998. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 44:249-254. (Pubitemid 28374114)
22. Li M, Chevalier-Larsen ES, Merry DE, Diamond MI. 2007. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem 282:3157-3164.
23. Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH. 2002. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet 11:1967-1976. (Pubitemid 34924907)
24. Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr HT, Zoghbi HY. 2008. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452:713-718.
25. Matsumoto H, Sasaki Y. 1989. Staurosporine, a protein kinase C inhibitor interferes with proliferation of arterial smooth muscle cells. Biochem Biophys Res Commun 158:105-109.
26. Orr HT, Zoghbi HY. 2007. Trinucleotide repeat disorders. Annu Rev Neurosci 30:575-621.
27. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG. 2007. Sirtuin 2 inhibitors rescue alpha-synuclein- mediated toxicity in models of Parkinson's disease. Science 317:516-519.
28. Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, Howell BW, Pennuto M. 2007. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 16:1593-1603.
29. Palazzolo I, Stack C, Kong L, Musaro A, Adachi H, Katsuno M, Sobue G, Taylor JP, Sumner CJ, Fischbeck KH, Pennuto M. 2009. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316-328.
30. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. 2007. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447:859-863.
31. Pennuto M, Fischbeck K. 2010. Therapeutic prospects for polyglutamine disease. In: Dobson CM, Ramirez-AlvaradoM, editors. Protein misfolding diseases: current and emerging principles. Hoboken, NJ: JohnWiley & Sons.
32. Perutz MF, Johnson T, Suzuki M, Finch JT. 1994. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 91:5355-5358.
33. Poletti A. 2004. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol 25:1-26.
34. Ross CA, Poirier MA. 2004. Protein aggregation and neurodegenerative disease. Nat Med 10(Suppl):S10-S17.
35. Rub U, de Vos RA, Brunt ER, Sebesteny T, Schols L, Auburger G, Bohl J, Ghebremedhin E, Gierga K, Seidel K, den Dunnen W, Heinsen H, Paulson H, Deller T. 2006. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol 16:218-227.
36. Saudou F, Finkbeiner S, Devys D, Greenberg ME. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66.
37. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. 2002. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59:770-772.
38. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. 2005. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A 102:11402-11407.
39. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, Miura M, Tabata T, Kato S. 2002. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855-864.
40. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. 1986. Staurosporine, a potent inhibitor of phospholipid/Ca2+-dependent protein kinase. Biochem Biophys Res Commun 135:397-402.
41. Taylor JP, Hardy J, Fischbeck KH. 2002. Toxic proteins in neurodegenerative disease. Science 296:1991-1995.
42. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, Fischbeck KH. 2003. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 12:749-757.
43. Thomas M, Dadgar N, Aphale A, Harrell JM, Kunkel R, Pratt WB, Lieberman AP. 2004. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem 279:8389-8395.
44. Thomas PS Jr, Fraley GS, Damian V, Woodke LB, Zapata F, Sopher BL, Plymate SR, La Spada AR. 2006. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum Mol Genet 15:2225-2238.
45. Walcott JL, Merry DE. 2002. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem 277:50855-50859.
46. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, Thomas PJ. 1999. Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 145:481-490.
47. Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, Lieberman AP. 2006. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest 116:2663-2672.
48. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293:493-498.